Access: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
Monzr M. Al Malki(City of Hope), Antonio Jimenez Jimenez(University of Miami), Bronwen E. Shaw(Royal Marsden NHS Foundation Trust), Eric Ndifon(National Marrow Donor Program), Muna Qayed(Emory University), Heather E. Stefanski(National Marrow Donor Program), Sung Won Choi(University of Michigan), Stephen R. Spellman(National Marrow Donor Program), Jeffery J. Auletta(Nationwide Children's Hospital), Larisa Broglie(Morgan Stanley Children's Hospital), Craig Malmberg(National Marrow Donor Program), Steven M. Devine(National Marrow Donor Program), Janelle A. Olson(National Marrow Donor Program), Brent R. Logan(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 6
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577